Research and Markets has announced the addition of the "Irritable Bowel Syndrome Pipeline Highlights - 2017" drug pipelines to their offering.

Irritable Bowel Syndrome Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Irritable Bowel Syndrome market. It covers emerging therapies for Irritable Bowel Syndrome in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Irritable Bowel Syndrome pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Irritable Bowel Syndrome pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Irritable Bowel Syndrome pipeline products by the company.

Short-term Launch Highlights:

Find out which Irritable Bowel Syndrome pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Irritable Bowel Syndrome Pipeline by Stages

2. Irritable Bowel Syndrome Pipeline by Drug Class

3. Irritable Bowel Syndrome Pipeline by Company

4. Irritable Bowel Syndrome Phase 3 Clinical Trial Insights

5. Irritable Bowel Syndrome Phase 2 Clinical Trial Insights

6. Irritable Bowel Syndrome Phase 1 Clinical Trial Insights

7. Irritable Bowel Syndrome Preclinical Research Insights

8. Irritable Bowel Syndrome Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/q4c6q8/irritable_bowel